Combination chemoradiotherapy with gemcitabine: Potential applications

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Gemcitabine (Gemzar) is a novel deoxycitidine drug that has demonstrated promising single-agent activity in non-small-cell lung cancer and has been proven to be a potent radiosensitizer. Although the exact mechanism of the radiosensitizing effect is unknown, several studies have focused on the drug's effect on deoxyadenosine triphosphate (dATP) pool depletion or cell-cycle manipulation. A number of trials have evaluated this feature of gemcitabine by combining chemotherapy and radiation in various doses and schedules, and those studies are described in this article. Gemcitabine appears to be a promising agent to be combined with radiation therapy. However, further clinical trials are needed to define optimal doses, toxicity, and efficacy.

Original languageEnglish (US)
Pages (from-to)20-25
Number of pages6
JournalONCOLOGY
Volume14
Issue number7 SUPPL. 4
StatePublished - Dec 1 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination chemoradiotherapy with gemcitabine: Potential applications'. Together they form a unique fingerprint.

  • Cite this